ARMP Armata Pharmaceuticals, Inc.

NYSE armatapharma.com


$ 4.95 $ -0.05 (-1.01 %)    

Friday, 31-Oct-2025 15:49:39 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 4.91
$ 5.08
$ 4.74 x 50
$ 5.25 x 250
$ 4.70 - $ 5.08
$ 0.90 - $ 16.34
52,365
na
177.89M
$ 0.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-21-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 08-14-2023 06-30-2023 10-Q
9 05-11-2023 03-31-2023 10-Q
10 03-16-2023 12-31-2022 10-K
11 11-09-2022 09-30-2022 10-Q
12 08-11-2022 06-30-2022 10-Q
13 05-12-2022 03-31-2022 10-Q
14 03-17-2022 12-31-2021 10-K
15 11-10-2021 09-30-2021 10-Q
16 08-12-2021 06-30-2021 10-Q
17 05-13-2021 03-31-2021 10-Q
18 03-18-2021 12-31-2020 10-K
19 11-12-2020 09-30-2020 10-Q
20 08-13-2020 06-30-2020 10-Q
21 05-14-2020 03-31-2020 10-Q
22 03-19-2020 12-31-2019 10-K
23 11-12-2019 09-30-2019 10-Q
24 08-14-2019 06-30-2019 10-Q
25 05-06-2019 03-31-2019 10-Q
26 03-25-2019 12-31-2018 10-K
27 11-08-2018 09-30-2018 10-Q
28 08-09-2018 06-30-2018 10-Q
29 05-15-2018 03-31-2018 10-Q
30 03-14-2018 12-31-2017 10-K
31 11-14-2017 09-30-2017 10-Q
32 08-14-2017 06-30-2017 10-Q
33 05-15-2017 03-31-2017 10-Q
34 03-27-2017 12-31-2016 10-K
35 11-10-2016 09-30-2016 10-Q
36 08-15-2016 06-30-2016 10-Q
37 05-12-2016 03-31-2016 10-Q
38 03-30-2016 12-31-2015 10-K
39 11-16-2015 09-30-2015 10-Q
40 08-13-2015 06-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 armata-pharmaceuticals-bacteriophage-therapy-shows-zero-relapse-in-phase-2a-sab-trial-paving-way-for-phase-3-in-2026

Data highlights:The Phase 2a study enrolled and dosed 42 patients, with 29 randomized to AP-SA02 in addition to BAT and 13 to p...

 armata-pharma-reports-results-from-its-recently-completed-phase-2a-disarm-study-of-ap-sa02-as-a-potential-treatment-for-complicated-staphylococcus-aureus-bacteremia-in-a-late-breaking-oral-presentation-at-idweek-2025

Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company fo...

 armata-pharmaceuticals-advances-cystic-fibrosis-infection-treatment-with-phage-research

Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company fo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION